Study of CIT-013 for hidradenitis suppurativa
Treatments studied
Part of Infections, Skin clinical trials.
This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had HS for more than 6 months
- You are 18 years or older
- You have HS bumps in at least 2 different body areas, with at least one area being stage II or III (moderate to severe)
- You currently have at least 5 inflamed bumps or abscesses
- Oral antibiotics haven't worked well enough, or you can't take them
- You have fewer than 20 draining tunnels (tracts under the skin)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
This trial is testing an experimental tablet called LT-002-158 in adults with moderate to severe hidradenitis suppurativa (HS) that hasn't improved enough with standard treatments. The goal is to see if it's safe and helps reduce painful lumps and abscesses.
This study looks at certain immune cells (called MAIT cells) in the skin of people with hidradenitis suppurativa, a painful skin condition. It will compare samples from people before they start a new biologic treatment, and may help doctors understand how these treatments work.
This trial tests a new drug called NAV-240 for people with hidradenitis suppurativa (HS) who have not had success with antibiotics. The goal is to see if the drug can reduce the number of painful lumps and improve symptoms.
This trial tests a new oral medication, soquelitinib, in adults with moderate-to-severe hidradenitis suppurativa (HS), the skin condition that causes painful lumps and tunnels. Soquelitinib works by calming the immune system to reduce inflammation. The study aims to see if it is safe and effective.
This trial tests a new cream (EVO101) for people with mild to moderate hidradenitis suppurativa (HS), a skin condition causing painful lumps. It aims to see if the cream can reduce the number of lesions. Participants cannot use certain other HS treatments during the study.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.